Crescent Biopharma raises capital via closing of public offering of ordinary shares and pre‑funded warrants, strengthening cash position for oncology pipeline
Executive summary: Crescent Biopharma closed a public offering of its ordinary shares and pre‑funded warrants, including the full exercise of the underwriters’ option to purchase additional shares. The offering provides Crescent Biopharma with additional funds to support its oncology drug development programs and general corporate purposes.
Who is involved: Crescent Biopharma, Inc. (Nasdaq: CBIO), its underwriters, and investors participating in the offering.
Likely next: The company will allocate the net proceeds to ongoing clinical trials and may file further registration statements for future capital needs.
Crescent Biopharma announced the completion of a public offering that included ordinary shares and pre‑funded warrants, with the underwriters’ option fully exercised. The transaction adds to the company’s liquidity as it advances clinical‑stage cancer therapies. No details on pricing or size were disclosed in the release.
Timeline
- — Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares (GlobeNewswire)
- — DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update (GlobeNewswire)
- — BNY Announces Pricing of Public Offering of $500,000,000 of Depositary Shares Representing Interests in Preferred Stock (PR Newswire)
Analysis — what this means
Sectors affected
- Biotechnology
Regulatory implications
- Subject to SEC registration under the Securities Act of 1933 and ongoing reporting under the Exchange Act of 1934.
Sources
- Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares — GlobeNewswire
- BNY Announces Pricing of Public Offering of $500,000,000 of Depositary Shares Representing Interests in Preferred Stock — PR Newswire
- DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update — GlobeNewswire